ArticleFrontiers in public health2025
Prevalence of virological failure and associated factors among adult individuals on highly active antiretroviral treatment (HAART) in public health facilities at Tulu Bolo Town, Southwest Shoa, Ethiopia, 2024.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prevalence and determinants of virologic failure among HIV patients on ART in Africa: A systematic review and meta-analysis.Virology journal · 2025Pooled it
- Viral suppression status and associated factors among key populations on ART in Western Oromia, Ethiopia: a retrospective analysis.AIDS research and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The goal of antiretroviral therapy for HIV infection is to achieve and maintain virological suppression. Review of charts of adult HIV-positive patients at public health facilities in Tulu Bolo Town reveals that approximately 6.07% of patients did not respond to first-line antiretroviral medication. The identified gap indicates that the study area's virological failure prevalence and contributing factors are not well-documented. Thus, this study's objectives are to evaluate prevalence and close a knowledge gap about factors associated with virological failure. Objective: The objective of this study was to assess the prevalence of virological failure and associated factors among patients taking highly active antiretroviral therapy in Tulu Bolo Town Health facilities, Oromia, Ethiopia, 2024. Methods: Health facility-based cross-sectional study was conducted at Tulu Bolo Town in public health facilities from 30 September 2024 to 30 October 2024. The total sample sizes of 274 records of clients were selected using simple random sampling technique. Data were cleaned and entered into EPI info version 7.2.0.1 and exported to SPSS version 20.0 for further analysis. The association was identified using binary logistic regression model. An adjusted odds ratio with 95% confidence intervals (CI) was computed to identify the presence and strength of association. Finally, statistically significant variables were declared at a Results: A total of 274 charts of HIV-positive clients were included in the study. The magnitude of virological failure was 12.8% (95%CI 9, 17%). Baseline CD4 count < 200 (AOR 6.1, 95%CI 2.06, 18.43), clients infected with TB (AOR 4.8 95%CI 1.78, 12.96), treatment interruption (AOR 3.05, 95% CI 1.06, 8.77), and adherence (AOR 3.67, 95%CI 1.39, 9.66) were statistically significant association. Conclusion and recommendation: The overall prevalence of virological failure of this study was high as compared to standard. Baseline CD4 count, TB infection, treatment interruption, and adherence were significant factors. Health facility ART provider and HIV/AIDS program manager should give special attention for clients with history of TB co-infection and CD4 count < 200 needs care and support and providing TB preventive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.